InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,588.27
(
-1.39%
)
US TECH 100
19,394.40
(
0.64%
)
Dow Jones
41,198.08
(
0.59%
)
Brent Oil
84.45
(
-0.05%
)
Bitcoin
64,930.11
(
1.32%
)
Post# of 13874
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Psionic Trader

Send PM Follow Ignore
Followers 1398
Posts 59304
Boards Moderated 6
Alias Born 11/08/2005

Psionic Trader

Re: None

Monday, 02/10/2014 9:02:17 PM

Monday, February 10, 2014 9:02:17 PM

Post# of 13874
$LJPC Phase2a estimated primary completion date: March 2014

The primary objective of this study is to compare the change in estimated glomerular filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment. The secondary objective is to determine the safety and tolerability of GCS-100 administered for 8 weeks relative to placebo. In addition, the study will measure the effect of GCS-100 on circulating galectin-3 and other markers of disease activity.

http://www.clinicaltrials.gov/ct2/show/record/NCT01843790?term=gcs-100&rank=3

Trading is fun @ Quick 2 Baggers Board

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up